Hyperkalemia After Starting an MRA in Heart Failure
A 66-year-old man with heart failure with reduced ejection fraction (EF 28%, NYHA class II) comes for routine follow-up. Three weeks ago spironolactone 25 mg daily was added to sacubitril/valsartan 24/26 mg twice daily, carvedilol 6.25 mg twice daily, furosemide 40 mg daily, and empagliflozin 10 mg daily. He feels well: blood pressure 112/70, heart rate 62, no edema, weight stable. He mentions he switched to a potassium-based salt substitute "for his heart" and has taken naproxen 220 mg twice daily since his knee began hurting. Today's labs: potassium 5.3 mmol/L (4.4 three weeks ago) and creatinine 1.7 mg/dL (1.4 three weeks ago), eGFR 32 mL/min/1.73 m².
1. Rank the contributors to his hyperkalemia and state what you would change today and what you would deliberately leave alone.
Read the worked answer
Potassium 5.3 with a creatinine bump is a signal, not an emergency - but several contributors are iatrogenic and fixable today.
Contributors, by yield:
- Potassium-based salt substitute - a direct, large, and easily reversed load.
- Naproxen - NSAID-induced afferent vasoconstriction causing AKI and reduced potassium excretion; also blunts diuretic effect.
- Spironolactone added 3 weeks ago - the timing fits perfectly.
- Underlying CKD (eGFR 32) with reduced reserve.
Change today: stop the salt substitute, stop naproxen (topical diclofenac or acetaminophen for the knee), hold or reduce spironolactone (5.3 sits at the top of the "reduce" band), dietary potassium counseling, and recheck potassium and creatinine in 3–7 days.
Leave alone: sacubitril/valsartan, carvedilol, and empagliflozin. All three carry mortality benefit, none is the likely culprit, and stopping them to chase a potassium of 5.3 trades a proven benefit for a small risk. The common error here is reflexive dismantling of guideline-directed therapy.
2. Can he stay on a mineralocorticoid receptor antagonist? Explain the thresholds and the tools available.
Read the worked answer
Yes - a potassium of 5.3 is an indication to optimize, not to abandon, unless it stays above 5.5 despite everything.
Reasonable sequence:
- Remove dietary and supplement sources; stop the NSAID; recheck in 3–7 days.
- If potassium remains 5.0–5.5: reduce spironolactone to 12.5 mg daily, or add a potassium binder - patiromer 8.4 g daily or sodium zirconium cyclosilicate 5–10 g daily - specifically to enable continued MRA/RAAS inhibition.
- True stop points: potassium persistently >5.5 despite measures, eGFR <30 (MRA initiation), symptomatic or ECG-positive hyperkalemia, or gynecomastia intolerance (switch to eplerenone).
Why it matters: MRA therapy reduces mortality and heart failure hospitalization in HFrEF; eplerenone/spironolactone benefit is lost if the drug is stopped. Document the reason for any dose change and a plan to rechallenge - "hold, recheck, restart" beats a permanent discontinuation that nobody revisits.
Also counsel on sick-day rules: hold the MRA, ARNI, and SGLT2 inhibitor during acute vomiting or dehydration, and recheck labs after any hospitalization.
3. Two months later he presents to the emergency department with palpitations and weakness. ECG shows peaked T waves and a widened QRS; potassium is 6.4 mmol/L. Outline your management in order.
Read the worked answer
6.4 with ECG changes is a cardiac emergency, not a lab follow-up.
1. Stabilize the membrane (first, always): IV calcium gluconate 10% 10–30 mL (or calcium chloride 10% 5–10 mL via a central line). Onset 1–3 minutes, duration 30–60 minutes. It does not lower potassium - the ECG may normalize while the potassium is still lethal. Repeat if ECG changes persist.
2. Shift potassium intracellularly: regular insulin 10 units IV with 25 g dextrose (monitor glucose hourly for at least 6 hours - hypoglycemia is a common late complication), plus nebulized albuterol 10–20 mg as an adjunct.
3. Remove potassium from the body: stop the salt substitute, NSAID, spironolactone, and any potassium supplements; furosemide if he is volume-repleted and making urine; sodium zirconium cyclosilicate or patiromer; hemodialysis if refractory, oliguric, or with ongoing ECG instability.
4. Monitor: continuous cardiac monitoring, repeat potassium in 1–2 hours (rebound after insulin is expected), and serial ECGs.
Afterward: this is the second avoidable episode. Reassess which agents he still needs, add a potassium binder if the MRA is to be continued, and make sure he has a written sick-day plan and a follow-up appointment before discharge.